Multi-stenting for the long lesion is a common practice, which, however, leads to prolonged intracoronary modifications. Additionally, with an increase in the stent length, the risk of restenosis gets increased. Hence, the long lesion stenting is a challenge for coronary interventionists. The present all-comer, real-world registry was designed to evaluate the clinical outcomes after implantation of long length newer-generation drug-eluting stents(DES).

The current registry included coronary artery disease patients who underwent percutaneous coronary intervention for single or multi-vessel disease between May 2013 and March 2017. All the enrolled patients were implanted with at least one long (≥38mm) length DES. The primary clinical endpoint was the cumulative incidences of major adverse cardiac events(MACE) consisted of cardiac death, myocardial infarction(MI), and target lesion revascularization(TLR) at an 18-month follow up.

A total of 507 lesions from295 (average age: 59.37 ± 10.52 years; males: 78.6%) enrolled patients were intervened successfully by deploying 296 long length newer-generation DES. Among the included patients, 65.1% had hypertension, 55.9% had diabetes mellitus. The target vessel was left descending artery in 47% of patients. The18-month cumulative incidence of MACE was 11(3.72%) consisted of 8(2.71%) cardiac deaths, 2(0.68%) MI and 1(0.34%) TLR. Additionally, there were 5(1.69%) incidences of stent thrombosis up to 18-months.

The newer-generation long length DES demonstrated a low MACE rate and favorable clinical outcomes when deployed in the high-risk long lesion real-world patients.